PDF(4132 KB)
The Nucleic Acid Detection and CRISPR-Based Microfluidic Point-of-Care Biosensing: Research and Applications
Zihao Zhao, Liang Zhao, Xiayan Wang
Prog Chem ›› 2025, Vol. 37 ›› Issue (10) : 1397-1409.
PDF(4132 KB)
PDF(4132 KB)
The Nucleic Acid Detection and CRISPR-Based Microfluidic Point-of-Care Biosensing: Research and Applications
Nucleic acid testing is the gold standard and technological cornerstone for the modern diagnosis of pathogenic infections. As a deployable public health surveillance technology, Point-of-Care Testing (POCT) has demonstrated significant value in infectious disease prevention and control, personalized precision medicine, and medical scenarios with limited resources. POCT technology can rapidly provide diagnostic information, significantly improve patient outcomes, and optimize the allocation of medical resources. As an emerging technology, microfluidic chips have become a key component in POCT due to their low reagent consumption, high integration, and automation. By integrating laboratory functions onto a single chip, microfluidic devices have achieved full-process automation of sample processing, signal amplification, and detection, greatly enhancing the efficiency and accuracy of testing. Moreover, when combined with isothermal amplification techniques (such as LAMP) and CRISPR-Cas technology, microfluidic chips can rapidly and sensitively detect pathogens, making them suitable for on-site screening of various infectious diseases. Currently, POCT devices based on microfluidic chips have been successfully applied in the detection of pathogens such as SARS-CoV-2, demonstrating the advantages of speed, portability, and high sensitivity. This review aims to summarize the development of nucleic acid detection and the research progress on the combination of CRISPR-Cas technology and microfluidic chips to explore their current applications and future prospects for POCT.
1 Introduction
2 Significance of point-of-care nucleic acid testing for pathogens
3 Conventional nucleic acid testing
3.1 PCR-Based nucleic acid testing
3.2 Isothermal-amplification-based pathogen nucleic acid testing
3.3 Other methods
4 CRISPR-Cas biosensor-based nucleic acid testing
4.1 Cas12a-Based nucleic acid detection
4.2 Cas13a-Based nucleic acid detection
4.3 Other CRISPR systems
5 CRISPR-Cas nucleic acid detection on microfluidic chips
5.1 Multiplexed detection on microfluidic chips
5.2 Amplification-free detection on microfluidic chips
5.3 Equipment-free microfluidic POCT for rapid detection
6 Conclusion and prospects
nucleic acid detection / point-of-care testing (POCT) technology / microfluidic chips / CRISRP-cas biosensing
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
(黄炎, 刘国东, 张学记. 化学进展, 2020, 32(9): 1241).
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
(赵欣, 肖迪. 中华预防医学杂志, 2024, 58(1): 98).
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
/
| 〈 |
|
〉 |